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Abstract
Background: Sensing of muramyl dipeptide (MDP) is impaired in Crohn’s disease (CD) patients with disease-linked variants
of the CARD15 (caspase activation and recruitment domain 15) gene. Animal studies suggest that normal CARD15 signalling
prevents inflammatory bowel disease, and may be important for disease development in CD. However, only a small fraction
of CD patients carry the disease linked CARD15 variants. The aim of this study was thus to investigate if changes could be
found in CARD15 signalling in patients without disease associated CARD15 variants.
Methodology/Principal Findings: By mapping the response to MDP in peripheral monocytes obtained from CD patients in
remission not receiving immunosuppresives, an impaired response to MDP was found in patients without disease linked
CARD15 variants compared to control monocytes. This impairment was accompanied by a decreased activation of IkB
kinase a/b (IKKa/b), the initial step in the nuclear factor kB (NFkB) pathway, whereas activation of mitogen-activated protein
(MAP)-kinases was unaffected. MDP additionally stimulates the inflammasome which is of importance for processing of
cytokines. The inflammasome was constitutively activated in CD, but unresponsive to MDP both in CD and control
monocytes.
Conclusions/Significance: These results suggest that inhibited MDP-dependent pathways in CD patients not carrying the
disease-associated CARD15 variants might be of importance for the pathogenesis of CD. The results reveal a dysfunctional
immune response in CD patients, not able to sense relevant stimuli on the one hand, and on the other hand possessing
constitutively active cytokine processing.
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Introduction
There is growing evidence of an impaired innate inflammatory
response playing a key role in the pathogenesis of Crohn’s disease
(CD) [1]. The innate immune system is based on the ability to
recognise pathogen-associated molecular patterns (PAMPs), like
flaggelin, CpG DNA, double stranded RNA and bacterial cell wall
constituents. The PAMPs are recognised by pattern recognition
receptors (PRRs) located both on the cell surface (the Toll-like
receptors), as well as intracellularly (the NOD-like receptors
(NLRs)) [2].
Three common variants of the NLR gene caspase activation
and recruitment domain 15 (CARD15, also known as nucleotide
binding and oligomerisation domain 2 (NOD2)) has been
associated with CD: SNP 8, 12 and 13 [3,4]. CARD15 recognises
the PAMP muramyl dipeptide (MDP), which is a peptidoglycan
constituent of the cell wall of both gram-negative and gram-
positive bacteria and is the minimal motif recognised by CARD15
[5]. Interaction between MDP and CARD15 leads to activation of
the nuclear factor kB (NFkB) by binding of the adaptor protein
RIP2 to CARD15 via caspase recruitment domains (CARDs) on
both proteins [5,6]. RIP2 activates NFkB both by down-regulation
of the NFkB inhibitor, IkBa, and by activation of the TAK1
kinase and the IkB Kinase (IKK) complex [7]. NFkB subsequently
translocates into the nucleus, where it acts as a transcription factor
for pro-inflammatory mediators, including the cytokines tumour
necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) [6]. CARD15
stimulation also leads to activation of the mitogen-activated
protein (MAP) kinases, p38 and JNK, through binding of CARD9
to CARD15 [8]. TAK1 has also been proposed to be an upstream
activator of MAP kinases [7].
MDP is also able to activate a pro-inflammatory response
directly, i.e. by activating the inflammasome, which in turn
activates the pro-inflammatory caspase 1 enzyme that cleaves the
pro-inflammatory cytokines IL-1b and IL-18 leading to their
activation [9]. MDP bind to NALP3 thereby facilitating binding to
ASC (apoptosis associated speck-like protein containing a CARD)
by a pyrin domain (PYD)-PYD interaction. ASC contains a
CARD domain that recruits pro-caspase 1, which is subsequently
cleaved and activated [10]. NALP1 has recently been shown to
possess a similar ability to sense MDP directly and interestingly
MDP activated CARD15 also activates NALP1 [11,12]. Activated
caspase 1 and IL-1b has been shown to be co-secreted into the
extracellular space [13].
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A number of studies have shown that the CARD15 variants
associated with CD cause impaired NFkB activation of peripheral
mononuclear cells [14–16]. However, other studies have shown a
gain-of-function phenotype for these mutations in monocytes
isolated from CARD15 mutated mice [17]. A recent study has
shown that monocytes from patients with the CARD15 mutations
have a decreased negative regulation of cytokine production
caused by high doses of MDP, consistent with a gain-of-function
phenotype [18]. The majority of studies on human cells, however,
point to a decreased inflammatory response to PAMPs in common
CD-associated CARD15 variants. Curiously, the studies that have
shown an impaired NFkB activation did not report direct effects of
CARD15 stimulation by MDP: Differences between non-mutated
and mutated CARD15 monocytes were observed in experiments
employing co-stimulation with MDP and PAMPs known to
stimulate PRRs other than CARD15 [14,18,19]. This suggests
crosstalk between different PRR pathways. Mutated CARD15
alleles are, however, only found in up to one fourth of the patients
with CD, which indicates that other mechanisms must be of
importance in the monocyte dysfunction [20].
The above-mentioned studies have mostly been performed on
unseparated circulating mononuclear blood cells, and the effects of
stimulation have been determined on cytokine production[14–
16,19]. Increased cytokine production in cells stimulated by
PAMPs could be caused by both activation of transcription
dependent (i.e. CARD15 dependent) pathways or via direct
stimulation of cytokine processing (i.e. inflammasome/CARD15
dependent) or a combination of these. Although we have
previously reported that pro-inflammatory caspases are upregu-
lated in ulcerative colitis [21], the role of the inflammasome
activation in CD disease remains unclear.
The aim of the present study was to determine the pattern of
response to MDP in CARD15 non-mutated monocytes from
patients with CD compared with CARD15 non-mutated mono-
cytes from control subjects. Both CARD15 and inflammasome
responses to pure MDP stimulations were determined in order to
elucidate whether alterations other than to CARD15, could be
involved in the pathogenesis of CD. Since MDP activates both
CARD15 pathways and the inflammasome, it was further
considered interesting to determine whether expression levels of
members of the inflammasome was affected by MDP stimulation.
Materials and Methods
Ethics Statement
The Scientific Ethics Committee of the Copenhagen Region
approved the study. All patients gave their written informed
consent before participation and the project fulfilled the Helsinki
V Declaration.
Patients and Genotyping of CARD15 Variants
18 patients with CD and 14 controls were included. Patients
with CD were eligible for enrolment only if they had quiescent
disease, and had not been administered any immunosuppressive
drugs one month prior to sampling. Disease activity was evaluated
by global assessment by the physician. Both CD patients and
control subjects were screened for the common CARD15 variants:
SNP8, SNP12, and SNP13 by the single strand conformation
polymorphism (SSCP)[22]. PCR amplification was performed
using primers for the polymorphic segments (exon 4e, exon 8, and
exon 111, respectively). PCR products were subsequently
separated on a SSCP gel. Subjects carrying any of the CARD15
variants were excluded. However, four patients homozygotic for
the SNP8 CARD15 variant were included as disease controls in
some experiments. CARD15 gene sequencing was not performed.
Isolation, Culturing, and Stimulation of Human
Monocytes
Venous blood was drawn in EDTA (10 mM) from the cubital
vein. Peripheral mononuclear cells were isolated by density
gradient centrifugation of blood diluted 1:1 in pyrogen free saline
over Ficoll-Paque (GE Healthcare Bio-sciences, Hillerød, Den-
mark). Monocytes were isolated by an indirect magnetic labelling
method allowing isolation of untouched monocytes from human
peripheral blood (Miltenyi Biotec, Bergish Gladbach, Germany).
Non-monocytes were labelled using biotin conjugated antibodies
against CD3, CD7, CD16, CD19, CD56, CD123, and glyco-
phorin A, followed by indirect magnetic labelling by anti-biotin
microbeads. The labelled cell suspension was transferred to a
MACS LS separation column resulting in the separation of
purified monocytes. Cells were kept at 4–8uC during the
separation steps. Monocyte purity was assessed by flow-cytometry
using fluorescence marked CD61, CD14, CD3, CD45 and IgG1
antibodies (Becton-Dickinson, Franklin Lakes, NJ, USA). Viability
was measured by trypan dye exclusion. Isolated monocytes were
kept in teflon wells (CCT-Europe, Ede, the Netherlands) and
grown in a humid 5% CO2 atmosphere at 37uC at a cell density of
1610
6 cells per well. The monocytes were cultured over night in
RPMI media (Invitrogen, Paisley, UK) supplemented with 10%
heat inactivated human serum (Cambrex, Vallensbæk, Denmark),
1 mM pyrovate, 50 mg/ml gentamycin, 50 mg/ml penicillin and
50 mg/ml streptomycin. For stimulation, the media was replaced
with Opti-Mem I Reduced Serum medium with antibiotics as
mentioned above and highly purified MDP (50 ng/ml–5 mg/ml)
(InvivoGen, San Diego, CA, USA). All materials were obtained
from Invitrogen unless otherwise stated. Cells were harvested after
0, 4, and 24 hours.
Monocyte Purity and Survival
The purity of monocytes was 91.4% (82.8–95.2). Viability after
cell separation determined by dye exclusion was .99%. Viability
remained high (.99%) after culture, and no differences were
observed in cells stimulated by MDP between controls and CD
patients.
RT qPCR
RNA from stimulated monocytes was isolated by NucleoSpin
columns (Macherey-Nagel, Du ¨ren, Germany). The amount of
RNA was measured by spectrophotometry. The integrity and
quality of the isolated RNA was determined by evaluation of RNA
electrophoresis for each sample. cDNA was synthesised from 1–
2 mg RNA by SuperScript III reverse transcriptase (Invitrogen,
Paisley, UK).
RT qPCR analysis was performed using Brilliant SYBR Green
QPCR Master Mix Kit and the PCR reaction was run on a
Stratagene Mx3000P thermocycler (Stratagene, La Jolla, CA, USA).
The primer sequences were taken from PrimerBank: IL-1b forward
CTCGCCAGTGAAATGATGGCT,IL-1b reverse GTCGGAGA-
TTCGTAGCTGGAT,TNF-aforward ATGAGCACTGAAAGC-
ATGATCC, TNF-a reverse GAGGGCTGATTAGAGAGAGG-
TC, caspase 1 forward AGTGCAGGACAACCCAGCTA, caspase
1 reverse AGATAATGAGAGCAAGACGTGTG, NALP3 forward
TCTCATGGATTGGTGAACAGC, NALP3 reverse GGTCC-
CCCAGAGAATTGTCA. The housekeeping gene Ribosomal
Protein, Large, P0 (RPLP0) was used as a loading control: RPLP0
forward GCTTCCTGGAGGGTGTCC, RPLP0 reverse GGA-
CARD15 Signalling in CD
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tive expression of the mRNA was calculated from a reference sample
taken from a pool of healthy donor monocytes stimulated for 4 hours.
Immunoblotting
Monocytes were lysed with RP1 lysis buffer (Macherey-Nagel,
Du ¨ren, Germany) and treated as according to the RNA-protein
purification protocol. The protein flow through was resolved in
RIPA buffer with 10% SDS. The samples were then heated at 95
uC for 5 minutes and run on a 4–12% gradient SDS acrylamaide
gel under reducing conditions. Proteins were transferred to a
Hypond ECL membrane (Amersham Biosciences, Freiburg,
Germany). After blocking with 5% milk, the membranes were
incubated with the appropriate primary antibodies overnight at
4uC and subsequently incubated with a horse radish peroxidase-
conjugated secondary antibody (DakoCytomation, Copenhagen,
Denmark) followed by ECL detection (Amersham). After blotting
with antibodies against phospho-proteins or the active forms, the
membranes were stripped and blotted with the unphosphorylated
form, followed by blotting with GAPDH for the loading control.
The primary antibodies were: IL-1b, active IL-1b, caspase 1,
active caspase 1, NALP3, ASC, CARD8, p38, IKKa/b, JNK and
GAPDH.
ELISA
To determine activity of the inflammasome, secreted caspase 1
and IL-1b was investigated by ELISA technique (caspase 1 assay
by R&D Systems, Minneapolis, MN, USA and IL-1b assay by
Amersham, Buckinghamshire, UK).
Statistics
Nonparametric statistics were applied. The Mann Whitney U
test was used to compare medians. A significance level of 0.05 was
applied.
Results
Effect of MDP on Cytokine Expression Levels
To determine whether CARD15 stimulation resulted in
expression of typical NFkB dependent pro-inflammatory cytokines,
the mRNA expression levels of TNF-a and IL-1b were measured in
monocytes from controls and from CD patients without disease
linkedCARD15mutations.Nodifferences inthe mRNAexpression
levels were seen at baseline between CD patients and controls.
Monocytes from control subjects had an increased TNF-a and IL-1b
expression at the mRNA level after 24 hours of MDP stimulation
(p,0.02 and p,0.01 respectively) (Fig. 1A and B). A similar
increased expression was seen after 4 hours, but this did not reach
Figure 1. Kinetics of MDP-induced mRNA expression of TNF-a and IL-1b. RT-qPCR of mRNA of TNF-a (A) and IL-1b (B). Kinetic studies of
mRNA-response (C and D). Isolated monocytes were stimulated for 5 minutes (0.08 hours), 4 hours and 24 hours. Stimulation with MDP increased the
level of mRNA transcription in monocytes from control subjects (p,0.01 and p,0.02 for TNF-a and IL-1b, respectively), whereas an upregulation was
not seen in monocytes isolated from CARD15 non-mutated CD patients. Arbitrary units. Due to high variability in IL1b expression in both control and
CD patients, these expression data were normalised to expression values at t=0 hours. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0007794.g001
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patients with CD(Fig. 1C and D). In contrast to this,CD patients had
no increase in cytokine mRNA expression levels when stimulated
with MDP. The expression level of TNF-a and IL-1b mRNA in
MDP-stimulated control monocytes was higher than in MDP-
stimulatedCDcells(p,0.04 and p=0.10, respectively).In contrast to
the mRNA expression results, a constitutively higher IL-1b
expression was found on the protein level in CD compared to
control (Fig. 2A). MDP stimulation did not alter the protein
expression of IL-1b in controls or CD patients.
Effect of MDP on Expression of NALP3-Inflammasome
Related Molecules
Expression of NALP3 mRNA was equal in CD and control
monocytes. The mRNA level was not altered by MDP stimulation
(Fig. 3A). Contrary to this, MDP stimulation clearly resulted in
increased caspase 1 expression in control monocytes, whereas a
similar effect was not seen in CD monocytes (p,0.03, Fig. 3B).
Basal caspase 1 expression was equal in control and CD
monocytes.
Analysis of Activation of Activation Pathways
Downstream of CARD15
Expression and phosphorylation of the p38 MAP kinase
pathway was subsequently investigated, as a marker to determine
if differences in downstream activation after CARD15 could
explain the decreased response to MDP in CD. There was no
detectable phospho-p38 in unstimulated controls and CD patients
with or without CD associated CARD15 variants (Fig. 2B).
Stimulation with MDP highly activated the p38 MAPK as seen by
increased amounts of phospho-p38. Interestingly, this increase was
found in both control and CD monocytes regardless of CARD15
status. Thus no major differences were found between control and
CD in activation of the p38 pathway. Contrary to CD monocytes,
control monocytes had an increased IKKa/b phosphorylation
without stimulation. The IKKa/b phosphorylation increased
substantially in MDP stimulated control monocytes compared to
CD monocytes, which had low or no detectable IKKa/b
phosphorylation upon MDP stimulation (Fig. 2C). No significant
differences were seen between CD monocytes regardless of
CARD15 variant status. This suggests that lack of NFkB activation
by MDP in CD could explain the decreased response to MDP.
Activation of the Inflammasome and IL-1b Maturation
Caspase 1 protein was constitutively highly expressed in CD
monocytes, and was cleaved to its active form in unstimulated cells
(Fig. 4A). No increases in the expression level or cleavage of
caspase 1 were seen upon stimulation with MDP neither in CD
nor in controls. Monocytes expressed the proteins of the NALP3-
inflammasome on the protein level: NALP3, ASC, and CARD8
(Fig. 5). Released activated caspase 1 to the media was, however,
equal in CD and control (data not shown). As described earlier the
Figure 2. MDP-induced expression IL-1b and activation of p38 and IKKa/b. Immunoblotting of IL-1b (A), p38 (B), and IKKa/b (C). Quatitative
IKKa/b phosphorylation, bars represent ranges (D). Monocytes were stimulated for 24 hours with MDP. IL-1b expression was increased in CD patients,
but no response was seen to MDP. Monocytes stimulated with MDP had increased p38 phosphorylation, regardless of disease status. Contrary to the
p38 response, reduced IKKa/b phosphorylation was seen in CD regardless of CARD15 status. Control monocytes did respond to MDP stimulation by
increasing IKKa/b phosphorylation. CD: Crohn’s disease. Crohn*: SNP8 homozygote.
doi:10.1371/journal.pone.0007794.g002
Figure 3. MDP-induced mRNA expression of NALP3 and caspase 1. RT-qPCR of mRNA of inflammasome member NALP3 (A) and caspase 1
(B). Arbitrary units. Isolated monocytes were stimulated for 24 hours. Stimulation with MDP increased the level of caspase 1 expression in control cells
(p,0.03), whereas such an increase was not found in CD monocytes.
doi:10.1371/journal.pone.0007794.g003
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controls. The amount of matured IL-1b was also increased in CD,
but in all cases IL-1b protein expression was independent of MDP
stimulation. The release of mature IL-1b was also independent on
disease stage and MDP stimulation and equal in CD and control
monocytes (Fig. 4B). This suggests that the inflammasome is
constitutively active in CD, but that the inflammasome activity is
not dependent on MDP stimulation in human monocytes, neither
in controls, nor in CD. The constitutively active caspase 1 found in
CD explain the increased expression of mature IL-1b in CD
compared to control monocytes.
Discussion
We describe an impaired response to MDP in monocytes from
CD patients without disease linked CARD15 variants. The
dysfunctional response is in accordance with the increasing
evidence of an impaired innate immune function in CD, and in
particular monocytes isolated from CD patients [1,23,24].
Upregulation of proinflammatory NFkB and MAP kinase
dependent cytokine gene transcription is the classic response to
activation of CARD15-dependent pathways [5,6]. It is interesting
to investigate a response to MDP, since this is the most specific
stimulus of CARD15 dependent pathways [5]. Decreased or
absent activation of CARD15 dependent pathways has previously
been described for three CARD15 variants associated with CD
[5,16,19,25], and the response was shown to be dependent on one
specific variant (SNP 13 (1007fs) homozygote) causing less
activation than the other two [14]. These studies have primarily
shown a decreased chemokine secretion in CD associated
CARD15 variants stimulated with MDP alone, whereas IL-1b
and TNF-a secretion was unaffected or not investigated. Non-
mutated CARD15 CD cells responded normally in terms of
cytokine secretion when co-stimulated with various PAMPs, but
no cytokine production was seen in cells only stimulated with
MDP in neither CD, nor control monocytes [19]. It has previously
been reported that MDP-dependent TNF-a secretion requires co-
stimulation with LPS or other PGN, whereas TNF-a mRNA is
greatly increased by MDP stimulation alone, but not translated
into TNF-a protein [26]. This is most likely the explanation for the
lack of increase in IL-1b protein expression and release seen in our
experiments compared to the above sited studies. Thus, we were
able to induce secretion of IL-1b with co-stimulation of monocytes
with LPS and MDP (data not shown).
Our results suggest that MDP regulated pathways are inhibited
in CARD15 non-mutated CD monocytes. It is possible that this
lack of response might be overruled by co-activation of other LRR
pathways, as some earlier published reports may indicate [16,25],
but it defines a unique response similar to CARD15 mutated
responses. Subsequent analysis of CARD15 dependent pathways
suggested that this difference was due to an impaired activation of
the classical NFkB pathway in both non-mutated and mutated
CARD15 monocytes, since MDP resulted in an impaired IKKa/
b-phosphorylation, the initial step in the activation of the NFkB
pathway. Interestingly, the monocytes from controls, CARD15
non-mutated CD patients, and CARD15 mutated CD patients
induced p38 phosphorylation in response to MDP, whereas no
detectable activation was seen on the JNK pathway. This pattern
of activation of MAPK pathways is similar to what previously have
been found in whole intestinal biopsies from patients with active
IBD [27]. Although the response seems to be normal, it is
interesting that it is seen in CARD15 mutated monocytes here.
The finding suggests that MDP dependent activation of p38
occurs through other MDP sensing PRRs in human monocytes. It
is, however, also reassuring that p38 is activated by MDP in CD
monocytes, as it confirms that control and CD cells have been
stimulated. It is unlikely that the stimulation could be due to TLR2
dependent signalling, since MDP alone has not been shown to
activate TLR2 [28]. The results reveal an impairment of a specific
NLR pathway in CD monocytes not carrying the disease
associated CARD15 variants, and therefore add evidence to the
theory of a dysfunctional innate immune response in CD
monocytes. It also emphasises that studies into the role of the
NLR pathway in CD monocytes should employ CARD15 non-
mutated CD monocytes as well as CARD15 non-mutated control
monocytes, since non-mutated CARD15 monocytes from CD
patients also appear to have dysfunctional PRR pathways. From
animal experimental studies there is increasing evidence of how
MDP-signalling seem to protect from inflammatory bowel disease.
Chronic MDP-stimulation thus seem to downregulate signalling
through other PRRs and protect mice from colitis [29,30].
Whether similar effects are to be found in human remain to be
investigated.
Figure 4. Caspase 1 processing and IL-1b release. Immunoblot-
ting of caspase 1 (A). CD patients had increased basal expression of pro-
caspase 1 and active cleaved caspase 1. No response was seen to MDP
stimulation. ELISA measurement of released active IL-1b (B). Media was
taken from monocytes stimulated for 24 hours with MDP. No
differences in IL-1b secretion were detected.
doi:10.1371/journal.pone.0007794.g004
Figure 5. Expression of inflammasome related proteins.
Immunoblotting of NALP3, ASC, and CARD8. Monocytes expressed all
these proteins involved in caspase 1 maturation.
doi:10.1371/journal.pone.0007794.g005
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stimulation of monocytes, the present study examined the effect of
MDP on inflammasome molecule expression and activation. It
was shown that caspase 1 expression on the mRNA level is
positively regulated by MDP stimulation, whereas NALP3
expression is unaltered. This has not previously been described.
Interestingly, this caspase 1-mRNA upregulation was inhibited in
CD CARD15 non-mutated monocytes, which further substanti-
ates a decreased MDP response in CD monocytes. In this
experimental setting MDP did not activate the inflammasome as
evidenced by a lack of caspase 1 cleavage. Thus, we found a
constitutive activation of the inflammasome in CD monocytes
regardless of the CARD15 status. This might contribute to the
pro-inflammatory state found in CD, and may suggest that
CARD15 acting as a scaffold protein for caspase 1 activation
remains intact. Whereas a similar pattern has previously been
described based on immunohistochemical double staining studies
[31], activation of the inflammasome in quiescent disease stages
has not earlier been reported. The constitutively active inflamma-
some/caspase 1 could explain the higher levels of maturated IL-1b
found in CD in this study.
In conclusion, this study shows that MDP-dependent pathways
are inhibited in CD monocytes without the disease associated
CARD15 variants, which indicates that the innate immune
response is deficient in CD. We found no evidence of a direct
activation of the inflammasome by MDP in human monocytes,
but an upregulation on the mRNA level of members of the
cytokine processing system, which was also impaired in CD. The
results indicate that future therapies aimed at restoring CARD15
signalling might be effective regardless of CARD15 status.
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